Floatz Rating
B57/100
Confidence
Indicative
Sponsor
UCB Biopharma SRL
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05543252CT.gov An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease | — | Terminated | — | — | — |
NCT04658186CT.gov A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease | — | Completed | — | — | — |
NCT04875962CT.gov A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Parkinson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Minzasolmin (this asset) | UCB Biopharma SRL | P2 | B · 57 |
| Safinamide | Zambon SpA | P4 | A |
| Cvt-301 | Acorda Therapeutics | P3 | A |
| Istradefylline | Georgetown University | P4 | BBB |
| Rasagiline | Guangzhou Henovcom Bioscience Co. Ltd. | P4 | BBB |
| Pardoprunox | Abbott Products | P3 | BBB |
| Opicapone | Bial - Portela C S.A. | P4 | BBB |
| Ropinirole | Titan Pharmaceuticals | P4 | BBB |
| Carbidopa | Tanta University | P4 | BBB |
+42 more in the Parkinson Disease cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Minzasolmin in Parkinson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/minzasolmin-parkinson-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →